Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ZGNX > SEC Filings for ZGNX > Form 8-K on 26-Mar-2014All Recent SEC Filings

Show all filings for ZOGENIX, INC.

Form 8-K for ZOGENIX, INC.


26-Mar-2014

Change in Directors or Principal Officers


Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 25, 2014, James B. Breitmeyer, M.D., Ph.D. accepted an appointment to fill a newly-created seat on Zogenix, Inc.'s (the "Company") Board of Directors (the "Board"), effective immediately. Based upon the recommendation of the Board's Nominating/Corporate Governance Committee, Dr. Breitmeyer was appointed as a Class II director, with an initial term expiring at the 2015 annual meeting of the Company's stockholders.

Dr. Breitmeyer, 60, currently serves as the President of Bavarian Nordic, Inc., an international biotechnology company, and also serves as the Executive Vice President at Bavarian Nordic A/S, positions he has held since February 2013. He served as acting Chief Medical Officer to the Company from August 2012 to February 2013. Dr. Breitmeyer served as Executive Vice President of Development and Chief Medical Officer of Cadence Pharmaceuticals, Inc., a biopharmaceutical company, from August 2006 to August 2012. He served as Chief Medical Officer of Applied Molecular Evolution, Inc., a wholly-owned subsidiary of Eli Lilly and Company, a global pharmaceutical company, from December 2001 to August 2006. From 2000 to 2001, Dr. Breitmeyer served as the President and Chief Executive Officer of the Harvard Clinical Research Institute. From 1991 to 2000, he held a variety of positions at Serono Laboratories Inc., a global biopharmaceutical company, including Chief Medical Officer and Senior Vice President of Research and Development. Prior to Serono Laboratories, he served as a consultant to ImmunoGen, Inc., and held clinical and teaching positions at the Dana Farber Cancer Institute and Harvard Medical School. Dr. Breitmeyer holds a B.A. in Chemistry from the University of California, Santa Cruz, an M.D. and Ph.D. from Washington University School of Medicine, and is Board Certified in Internal Medicine and Oncology.

In connection with his appointment to the Board, pursuant to the Company's independent director compensation policy, Dr. Breitmeyer has been granted an option to purchase 75,000 shares of the Company's common stock, which have an exercise price per share equal to $3.07, the fair market value of the Company's common stock on the date of grant. The options will vest over three years in thirty-six equal monthly installments, subject to his continuing service on the Board. Dr. Breitmeyer will also receive cash compensation for his service on the Board in accordance with the Company's independent director compensation policy, as such policy may be amended from time to time. There are no other arrangements or understandings between Dr. Breitmeyer and any other person pursuant to which he was selected to serve on the Board. There are no transactions in which the Company is a party and in which Dr. Breitmeyer has a material interest subject to disclosure under Item 404(a) of Regulation S-K.


  Add ZGNX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ZGNX - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.